We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
Read MoreHide Full Article
Key Takeaways
Medpace sees uneven trial demand, with metabolic programs steadier than oncology and cardiovascular.
MEDP says awards take three to five quarters to convert, extending the path from pipeline to revenue.
Medpace maintained solid EBITDA margins as AI spending is expected to outweigh savings through 2026-2027.
Medpace Holdings, Inc. (MEDP - Free Report) offers a focused view of how clinical research organization demand is changing in 2026.
The company’s growth story is not just about trial volume. It also turns on which therapeutic areas are holding up, how quickly awards convert to revenues, and whether technology spending can improve productivity later.
Medpace Shows a Split in Trial Demand
Demand across Medpace’s book is becoming more uneven by therapeutic area. Metabolic and GLP-1 programs have historically carried lower cancellation rates, giving that work a stabilizing role in backlog quality and utilization.
Oncology and cardiovascular have been the larger sources of recent cancellations. That matters because both remain important pieces of Medpace’s clinical-development base, and pressure in those areas can weigh on forward visibility even when other categories remain steadier.
The same theme is relevant across the broader clinical services group. IQVIA Holdings Inc. (IQV - Free Report) , which provides clinical research services, healthcare intelligence and technology solutions, is another name investors often watch when trial starts and sponsor spending patterns shift.
MEDP Awards Point to a Longer Conversion Cycle
Medpace’s early award signals are not translating into immediate revenues. Initial award notifications and win rates have improved, but many awards remain in pre-backlog before moving into active projects.
The timing gap is meaningful. Awards can take three to five quarters to start, which means improved pipeline activity may support later-period growth rather than near-term acceleration.
That delayed conversion cycle helps explain why backlog can support continuity without proving a sharp rebound. Medpace expects roughly $1.9 billion to $1.94 billion of backlog to convert into revenues over the next 12 months, but first-quarter net book-to-bill was 0.88X.
Image Source: Zacks Investment Research
Medpace Margins Benefit From Full-Service Focus
Medpace’s full-service model has helped protect profitability through mix changes. First-quarter EBITDA was $149.4 million, and EBITDA margin was 21.1%, nearly in line with 21.2% in the year-ago period.
That stability came despite elevated reimbursed out-of-pocket activity. Pass-throughs were roughly 44% of revenues in the quarter, creating mix noise that can make reported growth and booking comparisons harder to read.
Execution is becoming as important as volume. Improved employee retention, operating discipline and a centralized full-service platform give Medpace tools to defend margins while demand patterns normalize.
Charles River Laboratories International, Inc. (CRL - Free Report) gives investors another angle on outsourced research demand. Its preclinical and drug-development services sit earlier in the development chain, so its trends can complement what Phase I-IV focused companies reveal about clinical activity.
MEDP AI Spending Raises a Near-Term Question
Medpace’s technology investment adds another layer to the 2026 growth debate. Artificial intelligence spending is expected to exceed savings through 2026-2027, limiting the near-term productivity benefit.
That does not make the spending unimportant. It shows how healthcare-services companies may need to absorb upfront technology costs before automation, analytics or workflow improvements show up in margins.
For investors, the question is timing. AI can support better execution over time, but the current setup points to expense absorption before measurable operating leverage.
Medpace Scores Reflect Growth With Restraint
The bottom line is that Medpace sits in a healthier position than its softer booking signals suggest, but the trend picture still requires patience. Backlog conversion, metabolic exposure and durable margins support the story, while cancellations, longer start times and AI spending keep the near-term setup measured.
Medpace’s Style Scores sharpen that view. Its Growth Score of A points to attractive growth characteristics, while its Momentum Score of C is more neutral and its Value Score of D signals less obvious valuation support. The VGM Score of B suggests the broader style profile remains constructive, but not enough by itself to override the more restrained Zacks Rank #3 signal.
View the Zacks #1 Rank List
Image: Bigstock
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
Key Takeaways
Medpace Holdings, Inc. (MEDP - Free Report) offers a focused view of how clinical research organization demand is changing in 2026.
The company’s growth story is not just about trial volume. It also turns on which therapeutic areas are holding up, how quickly awards convert to revenues, and whether technology spending can improve productivity later.
Medpace Shows a Split in Trial Demand
Demand across Medpace’s book is becoming more uneven by therapeutic area. Metabolic and GLP-1 programs have historically carried lower cancellation rates, giving that work a stabilizing role in backlog quality and utilization.
Oncology and cardiovascular have been the larger sources of recent cancellations. That matters because both remain important pieces of Medpace’s clinical-development base, and pressure in those areas can weigh on forward visibility even when other categories remain steadier.
The same theme is relevant across the broader clinical services group. IQVIA Holdings Inc. (IQV - Free Report) , which provides clinical research services, healthcare intelligence and technology solutions, is another name investors often watch when trial starts and sponsor spending patterns shift.
MEDP Awards Point to a Longer Conversion Cycle
Medpace’s early award signals are not translating into immediate revenues. Initial award notifications and win rates have improved, but many awards remain in pre-backlog before moving into active projects.
The timing gap is meaningful. Awards can take three to five quarters to start, which means improved pipeline activity may support later-period growth rather than near-term acceleration.
That delayed conversion cycle helps explain why backlog can support continuity without proving a sharp rebound. Medpace expects roughly $1.9 billion to $1.94 billion of backlog to convert into revenues over the next 12 months, but first-quarter net book-to-bill was 0.88X.
Image Source: Zacks Investment Research
Medpace Margins Benefit From Full-Service Focus
Medpace’s full-service model has helped protect profitability through mix changes. First-quarter EBITDA was $149.4 million, and EBITDA margin was 21.1%, nearly in line with 21.2% in the year-ago period.
That stability came despite elevated reimbursed out-of-pocket activity. Pass-throughs were roughly 44% of revenues in the quarter, creating mix noise that can make reported growth and booking comparisons harder to read.
Execution is becoming as important as volume. Improved employee retention, operating discipline and a centralized full-service platform give Medpace tools to defend margins while demand patterns normalize.
Charles River Laboratories International, Inc. (CRL - Free Report) gives investors another angle on outsourced research demand. Its preclinical and drug-development services sit earlier in the development chain, so its trends can complement what Phase I-IV focused companies reveal about clinical activity.
MEDP AI Spending Raises a Near-Term Question
Medpace’s technology investment adds another layer to the 2026 growth debate. Artificial intelligence spending is expected to exceed savings through 2026-2027, limiting the near-term productivity benefit.
That does not make the spending unimportant. It shows how healthcare-services companies may need to absorb upfront technology costs before automation, analytics or workflow improvements show up in margins.
For investors, the question is timing. AI can support better execution over time, but the current setup points to expense absorption before measurable operating leverage.
Medpace Scores Reflect Growth With Restraint
The bottom line is that Medpace sits in a healthier position than its softer booking signals suggest, but the trend picture still requires patience. Backlog conversion, metabolic exposure and durable margins support the story, while cancellations, longer start times and AI spending keep the near-term setup measured.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). That indicates a more balanced short-term earnings-revision profile rather than a clear positive or negative signal. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Medpace’s Style Scores sharpen that view. Its Growth Score of A points to attractive growth characteristics, while its Momentum Score of C is more neutral and its Value Score of D signals less obvious valuation support. The VGM Score of B suggests the broader style profile remains constructive, but not enough by itself to override the more restrained Zacks Rank #3 signal.